Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Cuppone, Federica ^a   Bria, Emilio ^a,b   Vaccaro, Vanja ^a   Puglisi, Fabio ^c   Fabi, Alessandra ^a   Sperduti, Isabella ^a   Carlini, Paolo ^a   Milella, Michele ^a   Nisticò, Cecilia ^a   Russillo, Michelangelo ^a   Papaldo, Paola ^a   Ferretti, Gianluigi ^a   Aapro, Matti ^d   Giannarelli, Diana ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; DOCETAXEL; HORMONE RECEPTOR; PACLITAXEL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; META ANALYSIS; METASTASIS; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST TUMOR; CANCER STAGING; FEMALE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 79955845678     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-54     Document Type: Article

References (44)

1. Cancer Statistics. A Jemal R Siegel J Xu E Ward, CA: a cancer journal for clinicians 2010
2. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. NJ Petrelli EP Winer J Brahmer S Dubey S Smith C Thomas LT Vahdat J Obel N Vogelzang M Markman, et al. J Clin Oncol 2009 27 35 6052 6069 10.1200/JCO.2009.26.6171 19901123
3. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. F Cardoso E Senkus-Konefka L Fallowfield A Costa M Castiglione, Ann Oncol 21 Suppl 5 &2215 19
4. First-line chemotherapy with or without biologic agents for metastatic breast cancer. C Andreetta AM Minisini M Miscoria F Puglisi, Crit Rev Oncol Hematol 76 2 99 111
5. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. E Andreopoulou GN Hortobagyi, J Clin Oncol 2008 26 22 3660 3662 10.1200/JCO.2008.16.1026 18669447
6. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. V Guarneri P Conte, The oncologist 2009 14 7 645 656 10.1634/theoncologist.2009-0078 19608638
7. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. DJ Hicklin LM Ellis, J Clin Oncol 2005 23 5 1011 1027 15585754 (Pubitemid 46202320)
8. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. GE Konecny YG Meng M Untch HJ Wang I Bauerfeind M Epstein P Stieber JM Vernes J Gutierrez K Hong, et al. Clin Cancer Res 2004 10 5 1706 1716 10.1158/1078-0432.CCR-0951-3 15014023 (Pubitemid 38435562)
9. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. GW Sledge Jr, Semin Oncol 2002 29 3 Suppl 11 104 110 10.1053/sonc.2002.34062 12138404 (Pubitemid 34816072)
10. Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). G de Castro Junior F Puglisi E de Azambuja NS El Saghir A Awada, Crit Rev Oncol Hematol 2006 59 1 40 50 10.1016/j.critrevonc.2006.02.007 16600618 (Pubitemid 43903280)
11. Clearing the smoke on nicotine and angiogenesis. RK Jain, Nat Med 2001 7 7 775 777 10.1038/89889 11433337 (Pubitemid 32691628)
12. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. G Gasparini R Longo M Fanelli BA Teicher, J Clin Oncol 2005 23 6 1295 1311 10.1200/JCO.2005.10.022 15718328 (Pubitemid 46202288)
13. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. R Gray S Bhattacharya C Bowden K Miller RL Comis, J Clin Oncol 2009 27 30 4966 4972 10.1200/JCO.2008.21.6630 19720913
14. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. DW Miles A Chan LY Dirix J Cortes X Pivot P Tomczak T Delozier JH Sohn L Provencher F Puglisi, et al. J Clin Oncol 2011
15. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson, The New England journal of medicine 2007 357 26 2666 2676 10.1056/NEJMoa072113 18160686
16. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). NJ Robert V Dieras J Glaspy A Brufsky I Bondarenko O Lipatov E Perez D Yardley X Zhou S Phan, J Clin Oncol (Meeting Abstracts) 2009 27 15S 1005
17. Meta-analyses of randomised clinical trials in oncology. JP Pignon C Hill, The lancet oncology 2001 2 8 475 482 10.1016/S1470-2045(01)00453-3 11905723 (Pubitemid 33586302)
18. Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress?: a meta-analysis of 20 phase 3 trials. E Bria M Milella A Gelibter F Cuppone MS Pino EM Ruggeri P Carlini C Nistico E Terzoli F Cognetti, et al. Cancer 2007 110 3 525 533 10.1002/cncr.22809 17577216 (Pubitemid 47106140)
19. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. MK Parmar V Torri L Stewart, Statistics in medicine 1998 17 24 2815 2834 10.1002/(SICI)1097-0258(19981230)17:24<2815:: AID-SIM110>3.0.CO;2-8 9921604 (Pubitemid 28562978)
20. Practical methods for incorporating summary time-to-event data into meta-analysis. JF Tierney LA Stewart D Ghersi S Burdett MR Sydes, Trials 2007 8 16 10.1186/1745-6215-8-16 17555582
21. Cochrane handbook for Systematic Reviews of intervention 4.2.6 [updated sep 2006]. JPT Higgins S Green, The Cochrane Library Chichester, UK: John Wiley & Sons, Ltd 2006 vol. Issue 4
22. Interpreting measures of treatment effect in cancer clinical trials. LD Case G Kimmick ED Paskett K Lohman R Tucker, The oncologist 2002 7 3 181 187 10.1634/theoncologist.7-3-181 12065789 (Pubitemid 34651220)
23. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: Meta-analysis of randomized clinical trials. E Bria RJ Gralla H Raftopoulos F Cuppone M Milella I Sperduti P Carlini E Terzoli F Cognetti D Giannarelli, Lung Cancer 2008 63 1 50 7 18565615
24. Survival analysis: a practical approach. MKB Parmar D Machin, Chichester (England): John Wiley 1995
25. Confidence intervals for the number needed to treat. DG Altman, BMJ (Clinical research ed 1998 317 7168 1309 1312 (Pubitemid 28502420)
26. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer. A Brufsky I Bondarenko V Smirnov S Hurvitz E Perez O Ponomarova I Vynnychenko R Swamy H Mu R Rivera, Cancer Res 2009 69 42 (24-MeetingAbstracts)
27. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. KD Miller LI Chap FA Holmes MA Cobleigh PK Marcom L Fehrenbacher M Dickler BA Overmoyer JD Reimann AP Sing, et al. J Clin Oncol 2005 23 4 792 799 10.1200/JCO.2005.05.098 15681523 (Pubitemid 46224178)
28. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. KS Albain SM Nag G Calderillo-Ruiz JP Jordaan AC Llombart A Pluzanska J Rolski AS Melemed JM Reyes-Vidal JS Sekhon, et al. J Clin Oncol 2008 26 24 3950 3957 10.1200/JCO.2007.11.9362 18711184
29. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J O'Shaughnessy D Miles S Vukelja V Moiseyenko JP Ayoub G Cervantes P Fumoleau S Jones WY Lui L Mauriac, et al. J Clin Oncol 2002 20 12 2812 2823 10.1200/JCO.2002.09.002 12065558 (Pubitemid 34651510)
30. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. MJ Piccart-Gebhart T Burzykowski M Buyse G Sledge J Carmichael HJ Luck JR Mackey JM Nabholtz R Paridaens L Biganzoli, et al. J Clin Oncol 2008 26 12 1980 1986 10.1200/JCO.2007.10.8399 18421049
31. Detecting an overall survival benefit that is derived from progression-free survival. KR Broglio DA Berry, J Natl Cancer Inst 2009 101 23 1642 1649 10.1093/jnci/djp369 19903805
32. Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. JB Lee OH Woo KH Park SU Woo DS Yang AR Kim ES Lee YH Kim JS Kim JH Seo, Invest New Drugs 2009 29 1 182 8 19756376
33. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. A Valachis NP Polyzos NA Patsopoulos V Georgoulias D Mavroudis D Mauri, Breast Cancer Res Treat 122 1 1 7
34. Meta-analysis of patients (PTS) 65 years from three Randomized trials of Bevacizumab (BV) and first-line Chemotherapy as treatment for Metastatic Breast Cancer (MBC). DW Miles G Romieu V Dieras D Chen A Duenne N Robert, European Society for Medical Oncology (ESMO): 2010; Milan (ITALY) Annals of Oncology 2010 &22iii96 viii121 (#278PD) 21166507
35. Meta-analysis of patients (PTS) previously treated with Taxanes from three Randomized trials of Bevacizumab (BV) and first-line Chemotherapy as treatment for Metastatic Breast Cancer (MBC). DW Miles G Romieu V Dieras D Chen A Duenne J O'Shaughnessy, European Society for Medical Oncology (ESMO): 2010; Milan (ITALY) Annals of Oncology 2010 &22iii96 viii121 (#279PD) 21166507
36. Individualizing treatment decisions. The likelihood of being helped or harmed. SE Straus, Evaluation & the health professions 2002 25 2 210 224 21567995 (Pubitemid 34507361)
37. Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC). C Barrios M Liu S Lee L Vanlemmens J Ferrero T Tabei X Pivot H Iwata K Aogi M Brickman, et al. Cancer Res 2009 69 46 (24-MeetingAbstracts)
38. SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC). J Baselga Grupo Espanol de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores S H Roche F Costa J Getulio Martins Segalla H Pinczowski E Ma Ciruelos S Cabral Filho P Gomez B Van Eyll, Cancer Res 2009 69 45 (24-MeetingAbstracts) 19117986
39. A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC). W Gradishar V Kaklamani T Prasad Sahoo D Lokanatha V Raina S Bondarde M Jain, Cancer Res 2009 69 44 (24-MeetingAbstracts)
40. CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC). J Mackey S Hurvitz J Crown J Forbes H Roche T Pinter W Eiermann M Kennedy F Priou L Provencher, et al. Cancer Res 2009 69 47 (24-MeetingAbstracts) 10.1158/0008-5472.SABCS-09-47
41. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. TK Choueiri EL Mayer Y Je JE Rosenberg PL Nguyen GR Azzi J Bellmunt HJ Burstein FA Schutz, J Clin Oncol 29 6 632 638
42. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. V Ranpura S Hapani S Wu, Jama 305 5 487 494
43. Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side? N Verma SM Swain, J Clin Oncol 29 6 603 606
44. Bevacizumab treatment for solid tumors: boon or bust? DF Hayes, Jama 305 5 506 508